About PROMETHERA Biosciences
Promethera Biosciences is a clinical stage pharmaceutical company that develops innovative therapies for the treatment of liver diseases with no effective therapeutic cure.
Our mission is to discover, develop, and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells harvested from healthy human livers.
"One liver for several patients":
Our cell therapy products HepaStem and H2Stem are based on the use of allogeneic progenitor cells isolated from healthy adult human livers (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC). The innovation resides in both the simplicity of the treatment, which doesn’t require radical surgery (compared to liver transplantation), and in the wide variety of liver diseases that can be addressed with the same product, from rare inborn metabolic (orphan) diseases to acquired deficiencies such as acute alcoholic hepatitis or nonalcoholic steatohepatits in adults
Promethera Biosciences was founded in 2009 by the Technology Transfer Office of the Université Catholique de Louvain and Prof Etienne Sokal, based on the discovery made by the research and clinical team at UCL. Prof Sokal is a leading expert in hepatology and cell therapy.
The name of the Company was derived from the term "PROgenitor MEdicinal THERApies".
Promethera Biosciences has been funded by Venture Capital and grant and loans from the Walloon region (Belgium) since 2009 and a total of 67M Euros has been invested through three rounds of financing.
As of November 2015, Promethera Biosciences is constituted of a motivated team of 32 employees and governed by a seasoned management board.
PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01